GGrantIndex
← Leaderboards

Chung Yin Kong

Icahn School Of Medicine At Mount Sinai

$10,200,842
Attributed
$38,604,848
Total exposure
10
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.6M · FY200925
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$38,604,848 · 10

By mechanism

U01$23,746,043 · 4
R01$14,015,067 · 5
K25$843,738 · 1

Top collaborators

Most similar at Icahn School Of Medicine At Mount Sinai

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsScreeningMortalityCancer EtiologyMalignant Neoplasm Of LungCessation Of LifeModels And SimulationDecision MakingSmokingComorbidityCost EffectivenessClinical TrialsPoliciesNatural HistoryResearch PersonnelCancer Intervention And Surveillance Modeling NetworkCancer ControlBaseInnovationUnited StatesCancer ModelComparativeScreening For CancerFuture

Grant awards (49)

Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,554,893
U01 · FY2025 · CA
Optimizing Lung Cancer Screening Nodule Evaluation$700,213
R01 · FY2025 · CA · contact PI
Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors$697,894
R01 · FY2025 · CA
Optimizing Lung Cancer Screening in Cancer Survivors$688,469
R01 · FY2025 · CA
Comparative Modeling for the Prevention and Control of Uterine Cancer$630,059
U01 · FY2025 · CA
Comparative Modeling for the Prevention and Control of Uterine Cancer$803,402
U01 · FY2024 · CA
Optimizing Lung Cancer Screening Nodule Evaluation$665,198
R01 · FY2024 · CA · contact PI
Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors$663,802
R01 · FY2024 · CA
Optimizing Lung Cancer Screening in Cancer Survivors$654,045
R01 · FY2024 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,523,795
U01 · FY2023 · CA
Comparative Modeling for the Prevention and Control of Uterine Cancer$856,073
U01 · FY2023 · CA
Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors$712,969
R01 · FY2023 · CA
Optimizing Lung Cancer Screening Nodule Evaluation$686,206
R01 · FY2023 · CA · contact PI
Optimizing Lung Cancer Screening in Cancer Survivors$671,950
R01 · FY2023 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,600,160
U01 · FY2022 · CA
Comparative Modeling for the Prevention and Control of Uterine Cancer$933,993
U01 · FY2022 · CA
Optimizing Lung Cancer Screening Nodule Evaluation$686,206
R01 · FY2022 · CA · contact PI
Optimizing Lung Cancer Screening in Cancer Survivors$682,511
R01 · FY2022 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$101,571
U01 · FY2022 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$42,585
U01 · FY2022 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,732,423
U01 · FY2021 · CA
Comparative Modeling for the Prevention and Control of Uterine Cancer$947,887
U01 · FY2021 · CA
Optimizing Lung Cancer Screening Nodule Evaluation$751,936
R01 · FY2021 · CA · contact PI
Optimizing Lung Cancer Screening in Cancer Survivors$718,813
R01 · FY2021 · CA
Optimizing the Treatment of Pancreatic Adenocarcinoma$391,146
R01 · FY2021 · CA
CISNET Lung Disparities Supplement$74,000
U01 · FY2021 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,802,154
U01 · FY2020 · CA
Optimizing the Treatment of Pancreatic Adenocarcinoma$460,388
R01 · FY2020 · CA
Comparative Modeling of Lung Cancer Prevention and Control Policies$1,584,503
U01 · FY2019 · CA
Optimizing Treatment of Lung Cancer Patients with Comorbidities$682,087
R01 · FY2019 · CA
Optimizing the Treatment of Pancreatic Adenocarcinoma$381,565
R01 · FY2019 · CA
Optimizing the Treatment of Pancreatic Adenocarcinoma$69,242
R01 · FY2019 · CA
Comparative Modeling of Lung Cancer Prevention and Control Policies$1,644,588
U01 · FY2018 · CA
Optimizing Treatment of Lung Cancer Patients with Comorbidities$714,307
R01 · FY2018 · CA
Optimizing the Treatment of Pancreatic Adenocarcinoma$419,924
R01 · FY2018 · CA
Comparative Modeling of Lung Cancer Prevention and Control Policies$1,765,010
U01 · FY2017 · CA
Optimizing Treatment of Lung Cancer Patients with Comorbidities$730,394
R01 · FY2017 · CA
Optimizing the Treatment of Pancreatic Adenocarcinoma$398,519
R01 · FY2017 · CA
Comparative Modeling of Lung Cancer Prevention and Control Policies$1,680,258
U01 · FY2016 · CA
Optimizing Treatment of Lung Cancer Patients with Comorbidities$787,283
R01 · FY2016 · CA
Comparative Modeling of Lung Cancer Prevention and Control Policies$1,751,835
U01 · FY2015 · CA
Comparative Modeling of Lung Cancer Control Policies$1,326,517
U01 · FY2014 · CA · contact PI
Comparative Modeling of Lung Cancer Control Policies$99,250
U01 · FY2014 · CA · contact PI
Comparative Modeling of Lung Cancer Control Policies$1,291,087
U01 · FY2013 · CA · contact PI
Applications of Multi-Criteria Optimization (AMCO) to Cancer Simulation Modeling$168,926
K25 · FY2013 · CA · contact PI
Applications of Multi-Criteria Optimization (AMCO) to Cancer Simulation Modeling$170,124
K25 · FY2012 · CA · contact PI
Applications of Multi-Criteria Optimization (AMCO) to Cancer Simulation Modeling$172,499
K25 · FY2011 · CA · contact PI
Applications of Multi-Criteria Optimization (AMCO) to Cancer Simulation Modeling$168,363
K25 · FY2010 · CA · contact PI
Applications of Multi-Criteria Optimization (AMCO) to Cancer Simulation Modeling$163,826
K25 · FY2009 · CA · contact PI